Business Wire1d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
FDA accepts Arrowhead's NDA for plozasiran
Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...
FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease Treatment
Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
Arrowhead says FDA accepts NDA for investigational plozasiran
Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...
Healio1d
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’
In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
BioSpace9d
Biopharma Finishes 2024 Strong With ‘Robust’ VC, Upfront Payments: JP Morgan
J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 11,520 Shares
CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The ...
Equities Analysts Set Expectations for ARWR FY2025 Earnings
B. Riley upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on ...
Investing15d
B.Riley reiterates Buy rating on Arrowhead stock on siRNA therapeutics pipeline
On Friday, B.Riley analysts kept their Buy rating and a $51.00 price target for Arrowhead Pharma (NASDAQ:ARWR), underscoring the stock's potential. The firm's analysts emphasized Arrowhead's dominance ...